Normally, skin cells take about a month to form and rise to the surface. In people with psoriasis, this process happens in ...

Inverse psoriasis, which causes painful lesions on sensitive skin folds, can be hard to treat. Find out more about this type of psoriasis.

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to ...

A recent analysis of adverse drug reactions by Indian Pharmacopoeia Commission revealed that combinations of beta-blockers ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

Vyne Therapeutics has given up hopes of resuming a plaque psoriasis trial for its BET inhibitor placed on hold by the FDA, ...

Incidences of malignant neoplasms were low and stable with long-term ixekizumab treatment for people with psoriatic disease ...

Autoimmune diseases like lupus rheumatoid arthritis and psoriasis don’t just affect joints or skin they can silently damage ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...